Brief: Angle- Results Of Eisai Phase 2 Pilot study supports applicability of Parsortix-Based HER2 Assay For Use In ADC Clinical Trials
21/03/2025 07:33
March 21 (Reuters) - Angle PLC AGLE.L: ANGLE PLC - RESULTS OF EISAI PHASE 2 PILOT STUDY ANGLE PLC - NOW SEEKING TO ENGAGE WITH BLISSBIO IN ORDER TO WORK WITH THEM ON NEXT STAGE OF DEVELOPMENT OF BB-1701 ANGLE - BOTH DEVELOPED ASSAYS HAVE BEEN APPROVED FOR USE BY ASTRAZENECA AND CO CURRENTLY USING ASSAYS TO TEST BLOOD SAMPLES FROM PATIENTS ANGLE - RESULTS OF STUDY SUPPORTS CAPABILITY OF PARSORTIX SYSTEM FOR REAL-TIME ASSESSMENT OF BREAST CANCER PATIENT HER2 STATUS ANGLE PLC - RESULTS OF EISAI PHASE 2 PILOT STUDY SUPPORTS APPLICABILITY OF PARSORTIX-BASED HER2 ASSAY FOR USE IN ADC CLINICAL TRIALS Source text: ID:nRSU5993Ba Further company coverage: AGLE.L ((Reuters.Briefs@thomsonreuters.com;))